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Summary The possibility that weight loss in cancer patients may be augmented by tumour produced
catabolic factors, which stimulate lipid mobilisation, was investigated in a group of cancer patients with total
body weight loss ranging from 0 to 50%. The serum and urine lipolytic activity has been determined using
freshly isolated murine adipocytes in an in vitro assay. As a control group, we have used patients with
Alzheimer's disease, in which some patients may lose a considerable amount of weight, without an obvious
cause. The serum lipolytic activity for the Alzheimer's group with weight loss (0.11 ± 0.02 pmol glycerol
released 10 adipocytes-'ml' serum) was not significantly different from the group without weight loss
(0.11 ± 0.02 gmol glycerol released 105 adipocytes-ml-) or from a healthy control group (0.07 ± 0.02ytmol
glycerol released iOs adipocytesIml-'), but all three groups were significantly (P<0.005) lower than the
cancer patient group (0.20 ± 0.03ltmol glycerol I0 adipocytes-' ml-'), irrespective of weight loss. A similar
difference between the cancer and the control group was observed for the urinary lipolytic activity (0.67 ± 0.03
versus 0.28 ± 0.03 JLmol glycerol released 10 adipocytes-I mg creatinine-' respectively, P <0.01). Weight loss
in animals bearing the MAC16 adenocarcinoma was paralleled by a corresponding rise in serum lipolytic
activity which peaked when the loss of carcass weight was 16%. A similar decrease in serum lipolytic activity
was also observed in cancer patients at high percentages loss in body weight. However, a linear relationship
was observed between both the serum and urinary lipolytic activity and weight loss in cancer patients
(correlation coefficients 0.79 and 0.70 respectively) when the total body weight loss did not exceed 20%. This
suggests that weight loss in cancer patients may be attributed, at least in part, to an, as yet, unidentified
lipolytic factor.
Depletion of lipid stores is commonly found in cancer
patients and may account for the largest part of the weight
loss seen in cancer-bearing states (McAndrew, 1986). The
effect appears unrelated to nutrient intake, since pair-fed
animals do not lose as much fat as tumour-bearing animals
(Lundholm et al., 1981), and loss of body fat can occur in
the absence of anorexia (Beck & Tisdale, 1987). An increased
mobilisation of host adipose tissue may begin early in the
development of the tumour (Beck & Tisdale, 1987; Kralovic
et al., 1977), and in tumours which produce cachexia is
directly related to the tumour burden (Hollander et al.,
1986).
The mechanism for the increased mobilisation of host
lipids in the tumour-bearing state is unknown, but may be
related to the production of a lipolytic factor by the tumour
cells. Loss of body fat can be produced by the injection of a
non-viable preparation of Krebs-2-carcinoma, a tumour
capable of causing extensive fat depletion in the host (Costa
& Holland, 1962). Several lipolytic factors have been purified
or partially purified from tumour cells. Thus a 75,000 Dalton
protein, toxohormone L, has been isolated from tumour
extracts and body fluids of patients and and animals
(Masuno et al., 1981), which, when injected into animals was
capable of causing lipid mobilisation, immunosuppression
and involution of the thymus gland (Masuno et al., 1984).
An enhanced lipid mobilisation was also produced by serum
of mice bearing a thymic lymphoma (Kitada et al., 1980).
Serum from a patient with advanced cancer also produced a
similar effect (Kitada et al., 1981). Initial studies on this
factor indicated a molecular weight of about 5,000 Daltons,
while later studies showed that the low molecular weight
form was inactive, but aggregated on standing in the cold to
become active (Kitada et al., 1982). Recently we have demon-
strated a lipid mobilising factor in extracts of the MAC16
colon adenocarcinoma, a tumour capable of producing a
30% loss of host body weight with a tumour burden of only
3%, and without a drop in caloric intake (Beck & Tisdale,
1987). This material was also present in the serum suggesting
a peripheral effect of the tumour. Lipid mobilising factors
similar in charge and molecular weight to that found in the
MAC16 tumour have recently also been identified in the
serum of cachectic cancer patients.
These results suggest a generality of lipolytic factors in
experimental cancer, but few studies have been carried out in
patients. Production of lipolytic factors may be useful in the
initial diagnosis of cancer patients and in determining the
subsequent response to therapy. The level of such factors in
body fluids of patients with various degrees of weight loss,
with and without accompanying anorexia has been deter-
mined in the present study. As a control group we have used
patients with senile dementia of the Alzheimer type in which
patients may lose a considerable amount of weight with an
apparently normal food intake (Sing et al., 1988).
Materials and methods
Subjects
Twenty-four patients, 14 male and ten female with histo-
logically proven malignancy and varying degrees of weight
loss were entered into the study (Table I). None of the
patients were receiving therapy at the time of serum and
urine collection. Weight loss was calculated from the pre-
morbid weight. Appetite and food intake scores were
documented by the patients using a simple questionnaire and
linear analogue scale. In addition, 19 patients with senile
dementia of the Alzheimer type, ten with weight loss and
nine without, were also entered into the study (Table I). The
appetite and food intake of these patients was judged
clinically. Seven normal laboratory workers served as disease-
free controls. Blood samples were allowed to clot on ice for
60 min, centrifuged and the serum separated and divided into
five aliquots. Samples were stored at -70°C until assay.
Urine was collected at the same time as blood was removed.
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Table I Characterics of patients used in the study'
Diagnosis
Lung cancer (squamous)
Oesophageal cancer
Ovarian cancer
Lung cancer (oat)
Breast cancer
Colonic cancer
Non Hodgkins lymphoma
Hodgkins disease
Myeloma
Lung cancer (squamous)
Renal cancer
Liposarcoma
Renal cell carcinoma
Cervical cancer
Non Hodgkins lymphoma
Malignant teratoma
Lung cancer (squamous)
Lung cancer (squamous)
Breast cancer
Non Hodgkins lymphoma
Non Hodgkins lymphoma
Breast cancer
Malignant teratoma
Gastric carcinoma
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Weight
loss
(kg)
12
57-64
17
24
0
24
2
0
0
9
8f
27
2
3
5
5
5
4
7
7
18f
14
3
32
10
22
17
8
15
8
6.5
37
11
6.5
Duration of
weight loss
(weeks)
11
24
21
52
0
48
7
0
0
52
13
52
5
10
12
6
5
8
81
20
8
22
3
26
38
70
44
72
8
40
72
Total %b
weight
loss
17
50
15
36
0
36
4
0
0
18
11
28
9
25
6
6
6
8
14
10
20
18
3
43
17
39
26
17
27
18
12
45
20
14
Rate
weight loss
(kg/week)
1.06
2.67
0.82
0.46
0
0.5
0.29
0
0
0.17
0.60
0.51
0.46
0.34
0.38
0.83
0.9
0.5
0.08
0.35
2.09
0.64
0.87
1.2
0.26
0.24
0.18
0.09
4.63
0.28
0.08
State of
weight
loss'
Progressive
Static
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Static
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Progressive
Appetite
scored
2
2
3
1
3
2
2
3
3
1
2
3
1
2
2
2
3
2
3
2
2
2
2
1
3
3
3
3
3
3
3
3
3
3
Intake
scoree
2
3
I
3
2
2
3
3
2
3
2
2
2
4
3
3
1
3
2
1
2
2
1
3
3
3
3
3
3
3
3
3
3
'None of the patients was receiving therapy at the time of the study. bWeight loss as percentage of weight from which the weight loss is
calculated (usually, but not always, the pre-morbid weight). cSome patients may have lost significant weight, but not over the last few weeks.
d1 = no appetite, 2 = less than usual, 3 = usual, 4 = more than usual, 5 = much more than usual, as determined by patient. I1 = much less than
usual food intake, 2 = less than usual, 3 = usual, 4 = more than usual, 5 = much more than usual, as determined by patient. fAscites present:
weight loss probably an underestimate.
Animal studies
Female NMRI mice (obtained from our own colony) average
weight 20 g were transplanted with fragments of the MAC16
tumour into the flank as previously described (Beck & Tis-
dale, 1987). At 14 days after transplantation, when weight
loss was expected, blood was removed from the tail vein at
daily intervals. Body weight was also measured daily. Under
Home Office regulations, the experiment was terminated
when weight loss reached 30% of the initial body weight.
Plasma was prepared by centrifuging whole blood in a Beck-
man microfuge for 30s.
Determination oflipolytic activity
Mice (strain BKW) were killed by cervical dislocation and
their epididymal adipose tissue was removed and placed in
isotonic saline, minced and incubated at 37°C for 2 h in
Krebs Ringer bicarbonate buffer, pH 7.2, containing
2 mg ml-' of collagenase (Sigma Chemical Co., Dorset, UK)
with prior gassing with 95%02:5%C02. Digestion of the
tissue was detected by the disappearance of intact pieces and
an increased turbidity of the medium. Undigested material
and non-adipose matter was removed by allowing the fat
cells to float to the surface of the buffer and the supernatant
was aspirated and replaced with fresh buffer. The washing
procedure was repeated three times to remove all collagenase,
non-adipose cells and any endogenous hormones. After the
final wash the cells were suspended in an appropriate amount
of Krebs Ringer solution to give a density of 1.5 x 105
adipocytes ml-', the cell number being enumerated with a
Neubauer haemocytometer.
Cell samples (1 ml) were removed, with continuous mixing
to maintain a homogeneous cell suspension, added to the
appropriate test substance, gassed with 95%02:5%CO2 and
incubated for 2 h at 37°C in a shaking water bath. Control
samples containing adipocytes alone were also analysed to
Patient
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Sex
M
M
F
F
F
F
F
M
M
M
M
F
M
F
M
M
F
M
F
M
M
F
M
M
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
M
F
F
F
F
M
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measure any spontaneous glycerol release. When assaying
serum samples, a control (no adipocytes) was also included
to measure the initial amount of glycerol present in the
serum. Routinely samples of serum and urine (100 gl) were
assayed in duplicate and the assay was repeated four to five
times on each sample at different times using the separately
stored aliquots. At the end of the incubation period, 0.5 ml
of the incubation buffer was added to 0.5 ml of 10% (w/v)
perchloric acid and the mixture was shaken to ensure de-
proteinisation. The precipitated protein was sedimented by
centrifugation at 2,000 r.p.m. for 10 min, the supernatant
removed and neutralised with 20% (w/v) KOH, after which
the potassium perchlorate was sedimented by centrifugation
(2,000 r.p.m., 10 min) and the volume of the supernatant was
recorded and used to calculate the dilution factor. Assays on
the supernatant were performed either immediately, or after
storage at - 20°C for between 18 and 72 h. The concentra-
tion of glycerol was determined enzymatically on 200 il ali-
quots of the supernatant by the method of Wieland (1974).
The results are expressed as gmol glycerol released per ml of
serum or per mg creatinine in urine per 105 adipocytes minus
both the fat cell control value and the serum or urine control
value. Urinary creatinine concentration was determined
colorimetrically at 500 nm using a Sigma diagnostic kit
(Sigma Diagnostic, Poole, Dorset, UK).
Statistical analysis
Results are expressed as mean ± s.e.m. for at least five
separate determinations on a single patient when samples
were available. Differences were determined statistically using
Student's t test.
Results
The characteristics of the patients in this study are shown in
Table I. Total percentage body weight loss varied between 0
and 50% and the rate of weight loss varied between 0 and
4.6 kg per week. The average weight loss in the cancer
patient group (13.5 ± 2.9 kg) was not significantly different
from that in the Alzheimer's group (14.0 ± 3.0 kg). Of the 21
evaluable cancer patients with weight loss, 16 (76%) reported
a decrease in appetite and 15 (71%) reported a decreased
food intake. Of these 15 only five (36%) reported a much
greater decreased food intake than normal. All of the
patients with cancer, but with no weight loss, had normal
appetite and food intake scores. In general cancer patients
who reported a normal food intake had a lower rate of
weight loss (range 0-0.9 kg per week) compared with
10-12 10-11 10-1o 10-9 10-8 10-7 10-6 10-5 10-4
Log isoprenaline concentration (M)
Figure 1 Dose-response relationship for the ability of
isoprenaline to stimulate lipolysis, as measured by release of
FFA, from murine epididymal adipocytes. The concentration of
FFA in cell-free supernatants was determined immediately after
incubation using a Wako NEFA C kit (Alpha Laboraties Ltd.,
Hampshire, UK) as previously described (Beck & Tisdale, 1987).
patients with a reduced intake score (range 0.17-2.7 kg per
week). Both the appetite and intake scores were irrespective
of tumour type.
Serum lipolytic activity
The rate of glycerol release from murine adipocytes in re-
sponse to both serum and urine samples increased linearly
over a 3 h period, but tended to decrease with increasing time
of incubation, and for this reason 2 h was chosen as a
convenient incubation perioid for all samples. At the 2 h time
point there was a doubling in the amount ofglycerol released
when the sample volume was increased from 50 to 100jl4, but
the linearity did not extend above this range. For this reason,
and to obtain a larger change in absorbence value, the
sample volume was restricted to 100 gl for both urine and
serum. The serum and urine glycerol content was subtracted
from the final figures. In the case of urine samples this value
Table II Serum and urine lipolytic activity in cancer patientsa
Serum lipolytic activity Urine lipolytic activity
p.mol glycerol released g.mol glycerol released
lk5 adipocytes- 105 adipocytes'I
Patient ml-' mg creatinine'
1 0.36 0.03 1.02 0.04
2 0.09 0.01 0.50 0.05
3 0.14 ± 0.03 0.94 ± 0.03
4 0.18±0.03 0.23±0.03
5 0.22 0.02 0.56 0.06
6 0.12±0.01 0.83±0.07
7 0.20 ± 0.04 0.57 ± 0.02
8 0.16 0.01 0.33 0.03
9 0.12±0.01 0.31 0.02
10 0.22±0.04 0.60±0.12
11 0.31 ±0.03 0.28±0.02
12 0.12±0.01 0.45±0.06
13 0.12±0.02 0.27±0.01
14 0.11 0.06 0.40±0.10
15 0.23 0.04 1.10 0.08
16 0.22 ± 0.04 0.46 ± 0.02
17 0.11±0.03 0.38±0.06
18 0.09 0.02 0.18 0.03
19 0.10±0.02 1.11 0.04
20 0.33 ± 0.02 0.63 ± 0.02
21 0.20 0.02 0.48 ± 0.02
22 0.63 ± 0.00 1.22 ± 0.04
23 0.12 0.006 0.25 0.06
24 0.26 ± 0.01 0.81 ± 0.05
25 0.10 0.02
26 0.11±0.01
27 0.10 0.05
28 0.17 0.07
29 0.00 0.00
30 0.16±0.04
31 0.07 0.01
32 0.06 0.01
33 0.12 0.05
34 0.16±0.00
35 0.16 0.08
36 0.13±0.01
37 0.13 0.07
38 0.06 ± 0.00
39 0.01 ± 0.00
40 0.18±0.01 -
41 0.14 0.03 -
42 0.07 0.02 -
43 0.14 0.07 -
44 0.09 0.002 0.09 ± 0.02
45 0.00±O.00 0.50 ±O.09
46 0.13±0.01 0.59±0.08
47 0.02±0.001 0.09 ± 0.01
48 0.01 ± 0.001 0.09 ± 0.01
49 0.10±0.03 0.09±0.02
50 0.12 ± 0.03 0.50 ± 0.09
'Results are given as mean ± s.e.m. for at least five separate
determinations from individual patients, each determination being
performed in triplicate. Where single values are given insufficient
sample was available in separate aliquots for repeat experiments.WEIGHT LOSS IN CACHECTIC CANCER PATIENTS 819
tended to be zero. The validity of the assay was established
using isoprenaline as a positive control (Figure 1).
The serum lipid mobilising activity of patients with cancer,
Alzheimer's disease and normal healthy controls is given in
Table II. Preliminary experiments revealed that repeated
freezing and thawing of serum samples resulted in a progres-
sive loss of lipolytic activity. For this reason fresh serum
samples were divided into aliquots before freezing and only
the values obtained with freshly thawed samples are reported.
The average serum lipolytic activity for the Alzheimer's
group with weight loss (0.11 ±0.02;Lmol glycerol 105
adipocytes' ml-' serum) was not significantly different from
the group without weight loss (0.11 ± 0.02ytmol glycerol I05
adipocytes-'ml serum) or from the healthy control group
(0.07 ± 0.02 jmol glycerol I05 adipocytes'ml-' serum), but
all three groups were significantly lower (P <0.005) than the
cancer patient group (0.20 ± 0.03 ytmol glycerol 105
adipocytes-' ml-' serum) irrespective of whether weight loss
was apparent. Patients with cancer, but with no weight loss
also had a significantly higher serum lipolytic activity
(0.17 ± 0.03jtmol glycerol I05 adipocytes-' ml-' serum) than
the Alzheimer's group or healthy controls (P <0.001).
To try to understand variations in serum lipolytic activity
with weight loss, measurements have been made in animals
bearing the MAC16 adenocarcinoma, an experimental model
of cachexia. Animals transplanted with this tumour are a
heterogeneous group with weight loss appearing at various
times after tumour transplantation. Occasionally animals
bearing this tumour do not develop weight loss, although the
growth of the tumour is similar to those in which weight loss
is apparent. The results in Figure 2a show that for animals in
which weight loss occurs there is a rise in the plasma level of
lipolytic activity, which reaches a maximum when the animal
has lost 16% of the body weight (Figure 2b) and thereafter
decreases. Values of plasma lipolytic activity at all time
points from day 4 to day 7 are significantly (P <0.01) higher
than non-tumour-bearing controls. For animals without
weight loss there is no significant elevation in plasma lipolytic
activity above the value found in non tumour-bearing con-
trols (Figure 2c). This suggests a direct correlation between
the rise in plasma lipolytic activity and the weight loss,
although the relationship is only linear for the initial weight
loss.
A similar relationship between serum lipolytic activity and
weight loss was observed with the cancer patient group. Here
there was a linear relationship between serum lipolytic
activity and weight loss (correlation coefficient 0.79, n = 18)
only when the total loss of body weight did not exceed 20%
and weight loss was progressive (Figure 3). Patients with
higher percentage loss of body weight tended to have low
levels of serum lipolytic activity, and these patients all
reported a decrease in food intake, while a number of
patients with lower weight loss reported a normal food
intake. When only these subjects were included, the correla-
tion between serum lipolytic activity and weight loss im-
proved slightly (r = 0.84, n = 12) (Figure 4).
Patients with previous weight loss who were stable during
the study period had low levels of serum lipolytic activity
(patients two and 19 with values of 0.09 ± 0.01 and
0.10 ± 0.003imol glycerol released 105 adipocytes-' ml-'
serum respectively) that was not elevated significantly above
the controls.
Urine lipolytic activity
In general the values for the urine lipolytic activity were
qualitatively in line with the serum values (Table II). How-
ever, the accuracy of detection was determined by the total
volume of urine excreted since too dilute samples were below
the limits of glycerol measurement. To counteract differences
in urine volumes the urinary lipolytic activity has been ex-
pressed relative to the creatinine concentration of urine.
The urine lipolytic activity for all cancer patients
(0.67 ± 0.03 tmol glycerol released 105 adipocytes' mg
creatinine'1 urine) was significantly elevated above normal
a
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Figure 2 Changes in serum lipolytic activity (0) with weight
loss (0) in a, animals bearing the MAC16 tumour which lost
weight, b, variation in serum lipolytic activity of animals in a
with change in carcass weight, c, animals bearing the MAC16
tumour, but without weight loss. Results are expressed as
mean ± s.e.m. for four animals per group. Lipolytic activity is
expressed as ytmol glycerol released per 101 adipocytes per ml
plasma in a 2 h incubation. The average value for non-tumour-
bearing controls was 0.5 ± 0.2fsmol glycerol I01 adi-
pocytes-' ml-'.
controls (0.28 ± 0.03jtmol glycerol released 105 adi-
pocytes-' mg creatinine-';P <0.01). However, there was no
significant difference in the non-weight losing cancer patients
and controls unlike the serum value. A similar biphasic rise
and fall of lipolytic activity with weight loss was observed.
However, when only patients with weight loss less than 20%
body weight were considered there was a linear relationship
(r = 0.70, n = 17) between the urine lipolytic activity and
weight loss for all patients (Figure 5). There was no correla-
tion between the urinary lipolytic activity and the rate of
weight loss.
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Discussion
A rapid reduction in the total quantity of
demonstrated in patients with cancer (Wai
panied by hypermetabolism and an incre
fat. Diminished insulin secretion and rt
considered to enhance lipid mobilisation
(Argiles & Azcon-Bieto, 1988), but 1
confirms the existence of an as yet ur
factor in the serum and urine of cance
without weight loss. This factor lacks species specificity in
Es that the human material is able to stimulate lipolysis in
murine adipocytes.
In animals bearing the MAC16 adenocarcinoma, an ex-
perimental tumour inducing weight loss in some, but not all
recipient animals, plasma levels of lipolytic activity were only
elevated in animals in which weight loss occurred. This sug-
gests a direct correlation between this lipid mobilising factor
and the induction of weight loss, and this correlation has
been strengthened by the observation that the polyun-
saturated fatty acid, eicosapentaenoic acid, is an inhibitor of
both the tumour lipid mobilising factor and the weight loss
in animals bearing the MAC16 tumour (Tisdale & Beck,
1'2 14 1'6 unpublished). In animals bearing the MAC16 tumour there is
only a linear correlation between the plasma level of the
lipolytic factor and weight loss, when the total loss of body
olytic activity and weight did not exceed 16%. Above this level plasma levels of
e lipolytic activity is lipolytic activity decreased with increasing weight loss. The
adipocytes in a 2 h mechanism of regulation of serum lipid mobilising activity is
not known.
We have utilised freshly prepared murine adipocytes to
investigate the lipolytic activity of patient samples in
preference to slices of adipose tissue or cultured adipocytes.
X Free fat cells generally respond to all hormones which affect
intact tissues and have a greater lipolytic response than pieces
ofadipose tissue incubated in vitro (Fair, 1973). The response
of different preparations of adipocytes is somewhat variable
and therefore we have carried out the experiments on at least
five different occasions where sample volume permitted. The
response of the adipocyte preparations has been standardised
using isoprenaline as a positive control. All fat cell prepara-
tions release glycerol in the absence of a lipolytic agent. This
blank figure is somewhat variable due to differences in the
adipocyte preparation, but is subtracted from the final
figures. The values for the lipolytic activity of serum samples
1'2 14 1'6 decreased on repeated freezing and thawing and therefore
only values are included where the sample was not re-frozen.
In some cases this did not give sufficient results for statistical
)olytic activity and analysis.
irting a normal food While the serum lipolytic activity of the cancer patient
group was significantly elevated over that ofhealthy controls,
patients with Alzheimer's disease and weight loss comparable
to that found in the cancer patients did not differ either from
Alzheimer's patients without weight loss or from healthy
* controls. This suggests that elevation of serum lipolytic
activity is not common in all weight losing situations and
may be specific for the neoplastic state.
When only patients with weight loss less than 20% of body
weight are considered there is a good correlation between the
level of the serum and urinary lipolytic activity and the
extent of weight loss, as for the MAC16 tumour. Patients
with weight loss greater than 20% of body weight have low
serum levels of lipolytic activity and in these patients
anorexia was invariably present. This suggests that a tumour-
produced lipolytic factor may be important in weight loss,
particularly when anorexia is absent.
12 14 16 Anorexia is commonly reported in cancer patients (Bern-
stein, 1986) and in our study a high percentage (70%) of the
weight losing cancer patients, reported a decrease in appetite
polytic activity and and food intake. This was, however, only a subjective assess-
e lipolytic activity is ment by the patients and anorexia is sometimes denied by the
adipocytes in a 2 h patient even though it may be present (Wesdorp et al., 1986).
However, detailed studies have shown that the energy intake
in ten cancer patients, who were below normal body weight
and body cell mass, did not differ significantly from that of
nine non-neoplastic control subjects, with diseases affecting
physical activity to about the same extent (Warnold, et al.,
r body fat has been 1978). Both the daily energy expenditure and the resting
tkin, 1959), accom- metabolic rate were significantly greater in the cancer
eased utilisation of patients than in the controls. Since lipids have a high calorific
esistance has been value, they are probably important in maintaining the high
in cancer cachexia metabolic rate in cancer patients, and an increased lipid
the present study requirement in cancer patients is suggested, since the rate of
identified lipolytic removal of infused lipids from the blood appears to be
r patients with or increased (Waterhouse & Nye, 1961). Thus a lipolytic factor
r
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may be important in cancer patients for providing increased
lipid mobilisation under conditions where it might not be
expected to occur, e.g. when the energy intake is normal.
It is also known that a number of tumours have a limited
ability to synthesise fatty acids and obtain a substantial
amount preformed from the host (Spector & Bums, 1987).
Such fatty acids after only minor structural modification are
incorporated into all of the complex lipids formed by the
tumour cells, including the phospholipids needed for mem-
brane synthesis and the formation of important regulatory
metabolites such as eicosanoids and diacylglycerol. Thus the
elaboration of a lipolytic factor may be essential for the
growth and reproduction of neoplastic cells. However,
measurement ofthe rate ofwhole body lipolysis in man using
the glycerol turnover rate has shown no difference between
cancer patients and controls (Jeevanandam et al., 1986),
although another study using the same technique reported an
elevated glycerol turnover in progressive cancer (Eden et al.,
1985). Thus, whether the loss of body fat in patients with
cancer cachexia is due to a reduced rate of lipogenesis or an
augmented lipolysis still remains controversial, although our
results would support the latter hypothesis.
The only urinary lipolytic factor so far described in
humans was obtained from fasting subjects with intact
pituitaries (Kekwick & Pawan, 1967) and has many of the
characteristics of a cachectic factor. Thus when injected into
mice this material mobilises body fat, increases the total
metabolic turnover and causes weight loss without depressing
appetite (Chalmers et al., 1958). Another postulated cachectic
factor, tumour necrosis factor/chachectin (TNF) produced by
activated macrophages, may be correlated with appetite sup-
pression and anorexia, but has no direct lipolytic activity in
an in vitro assay (Mahony et al., 1988). Furthermore, using a
sensitive radioimmunoassay TNF was not detectable in the
serum of patients with clinical cancer cachexia (Socher et al.,
1988). For this reason no estimation of the levels ofTNF has
been made in the present study.
The nature of the serum and urinary lipolytic factor found
in the present study awaits its purification although
preliminary results suggest that the material differs from the
lipolytic hormones found in normal serum and is similar to
the lipid mobilising factor elaborated by the cachexia-
inducing MAC16 adenocarcinoma in both charge and
molecular weight. However, the elevated levels found in
cancer patients may be a useful aid in the initial diagnosis of
the disease and further studies will determine the response to
therapy.
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